EE03875B1 - S-omeprasooli uus vorm - Google Patents

S-omeprasooli uus vorm

Info

Publication number
EE03875B1
EE03875B1 EEP199900550A EEP9900550A EE03875B1 EE 03875 B1 EE03875 B1 EE 03875B1 EE P199900550 A EEP199900550 A EE P199900550A EE P9900550 A EEP9900550 A EE P9900550A EE 03875 B1 EE03875 B1 EE 03875B1
Authority
EE
Estonia
Prior art keywords
omeprazole
new form
new
Prior art date
Application number
EEP199900550A
Other languages
English (en)
Inventor
Kristina Cotton Hanna
Kronstr�m Anders
Mattson Anders
M�ller Eva
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03875(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of EE9900550A publication Critical patent/EE9900550A/et
Publication of EE03875B1 publication Critical patent/EE03875B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
EEP199900550A 1997-05-30 1998-05-25 S-omeprasooli uus vorm EE03875B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702065A SE510650C2 (sv) 1997-05-30 1997-05-30 Ny förening
PCT/SE1998/000974 WO1998054171A1 (en) 1997-05-30 1998-05-25 Novel form of s-omeprazole

Publications (2)

Publication Number Publication Date
EE9900550A EE9900550A (et) 2000-06-15
EE03875B1 true EE03875B1 (et) 2002-10-15

Family

ID=20407186

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900550A EE03875B1 (et) 1997-05-30 1998-05-25 S-omeprasooli uus vorm

Country Status (44)

Country Link
US (6) US6369085B1 (et)
EP (2) EP0984957B3 (et)
JP (2) JP4002303B2 (et)
KR (2) KR100527804B1 (et)
CN (1) CN1161351C (et)
AR (2) AR012717A1 (et)
AT (2) ATE291574T1 (et)
AU (1) AU722839B2 (et)
BR (1) BR9809509A (et)
CA (2) CA2521391C (et)
CY (1) CY2012029I1 (et)
CZ (1) CZ297585B6 (et)
DE (3) DE69814069T3 (et)
DK (2) DK1273581T3 (et)
DZ (1) DZ2495A1 (et)
EE (1) EE03875B1 (et)
EG (1) EG24291A (et)
ES (2) ES2195345T7 (et)
HK (2) HK1051681A1 (et)
HR (1) HRP980263B1 (et)
HU (1) HU225987B1 (et)
ID (1) ID29306A (et)
IL (1) IL132947A0 (et)
IS (2) IS2142B (et)
LU (2) LU91871I2 (et)
MA (1) MA26500A1 (et)
ME (3) MEP24908A (et)
MY (2) MY127793A (et)
NO (3) NO317518B1 (et)
NZ (1) NZ500991A (et)
PL (1) PL193546B1 (et)
PT (2) PT1273581E (et)
RS (2) RS50067B (et)
RU (1) RU2184115C2 (et)
SA (2) SA05260296B1 (et)
SE (1) SE510650C2 (et)
SI (2) SI0984957T1 (et)
SK (2) SK285137B6 (et)
TN (1) TNSN98074A1 (et)
TR (1) TR199902934T2 (et)
TW (1) TW538040B (et)
UA (1) UA60334C2 (et)
WO (1) WO1998054171A1 (et)
ZA (1) ZA984179B (et)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
ATE355375T1 (de) 1996-01-04 2006-03-15 Novartis Vaccines & Diagnostic Bakterioferritin aus helicobacter pylori
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DK1487818T3 (da) * 2002-03-05 2007-08-20 Astrazeneca Ab Alkylammoniumsalte af omeprazol og esomeprazol
WO2003089408A2 (en) * 2002-04-22 2003-10-30 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
EP1515963B1 (en) 2002-06-27 2007-02-14 Dr. Reddy's Laboratories Ltd. A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
CN100378093C (zh) * 2002-06-27 2008-04-02 雷迪实验室有限公司 一种制备包括无定形艾美拉唑及其盐在内的光学纯或光学浓缩的亚砜化合物的方法
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
AU2003262992A1 (en) * 2002-08-30 2004-03-19 Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
US8697094B2 (en) * 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
BR0315574A (pt) * 2002-10-22 2005-09-20 Ranbaxy Lab Ltd Forma amorfa de esomeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
WO2004060263A2 (en) * 2003-01-07 2004-07-22 Ranbaxy Laboratories Limited Magnesium salt of imidazole derivative
WO2004089935A1 (en) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
WO2004099181A1 (en) 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005011692A1 (en) * 2003-07-23 2005-02-10 Altana Pharma Ag Alkaline salts of proton pump inhibitors
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
AU2005216862A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
US20070161679A1 (en) * 2004-02-18 2007-07-12 Allergan, Inc. Method and compositions for the intravenous administration of compounds related to proton pump inhibitors
MXPA06011820A (es) * 2004-04-16 2006-12-15 Santarus Inc Combinacion de inhibidor de bomba de proton, agente regulador del ph y agente procinetico.
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
EP1765806A1 (en) * 2004-06-24 2007-03-28 AstraZeneca AB New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
ES2246149B1 (es) 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
KR20080007508A (ko) * 2005-05-06 2008-01-21 그렌마크 파머수티칼스 엘티디. 에소메프라졸 스트론튬염, 그것의 제조방법 및 그것을함유하는 약제학적 조성물
WO2006134605A1 (en) 2005-06-15 2006-12-21 Hetero Drugs Limited Amorphous esomeprazole hydrate
EP1904064A4 (en) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr OMEPRAZOLE OF FORM B
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
KR100641534B1 (ko) 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US7576219B2 (en) * 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
JP5017274B2 (ja) * 2005-10-26 2012-09-05 ハンミ・サイエンス・カンパニー・リミテッド Ｓ−オメプラゾールストロンチウム塩またはその水和物、その製造方法、及びこれを含む医薬組成物
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) * 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
EP2040710A2 (en) * 2006-06-21 2009-04-01 Glenmark Pharmaceuticals Limited Novel polymorph of esomeprazole potassium and process for its preparation
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
EP2114919A2 (en) 2007-01-31 2009-11-11 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic seperation
AU2008217603C1 (en) * 2007-02-21 2013-08-15 Cipla Limited Process for the preparation of esomeprazole magnesium dihydrate
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
EP2000468A1 (en) 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
EP2152691B1 (en) * 2007-06-07 2011-11-23 Aurobindo Pharma Limited An improved process for preparing an optically active proton pump inhibitor
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
US8106210B2 (en) * 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
KR20170097787A (ko) 2007-10-12 2017-08-28 다케다 파마슈티칼스 유에스에이, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
WO2009099933A2 (en) * 2008-02-01 2009-08-13 Dr. Reddy's Laboratories Ltd. Preparation of esomeprazole magnesium and hydrates thereof
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) * 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
MX2011002515A (es) 2008-09-09 2011-04-07 Astrazeneca Ab Metodo de administracion de una composicion farmaceutica a un paciente que lo necesita.
CN101391993B (zh) * 2008-10-28 2012-07-04 安徽美诺华药物化学有限公司 通过与(s)-(-)-1,1'-联萘-2,2'-二酚形成包合配合物制备s-奥美拉唑及其盐的方法
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
US20100267959A1 (en) * 2009-04-15 2010-10-21 Glenmark Generics Limited Process for the preparation of esomeprazole magnesium dihydrate
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
US20130030186A1 (en) * 2009-06-02 2013-01-31 Sun Pharmaceutical Industries Limited Process for preparing sulphoxide compounds
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
US20110008432A1 (en) * 2009-06-25 2011-01-13 Pozen Inc. Method for Treating a Patient in Need of Aspirin Therapy
WO2011012957A1 (en) * 2009-07-29 2011-02-03 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of esomeprazole magnesium dihydrate
US8748619B2 (en) 2009-11-12 2014-06-10 Hetero Research Foundation Process for the resolution of omeprazole
EP2510089B1 (en) 2009-12-08 2015-10-21 Codexis, Inc. Synthesis of prazole compounds
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
FR2959509B1 (fr) 2010-05-03 2012-07-13 Prod Chim Auxiliaires Et De Synthese Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole
CN102241668B (zh) * 2010-05-11 2015-11-25 中国科学院成都有机化学有限公司 S-奥美拉唑盐
EP2649187B1 (en) 2010-12-08 2017-11-22 Codexis, Inc. Biocatalysts and methods for the synthesis of armodafinil
CN102757421A (zh) * 2011-04-29 2012-10-31 江苏正大天晴药业股份有限公司 埃索美拉唑的纯化方法
CN102911158B (zh) * 2011-07-31 2015-07-22 连云港润众制药有限公司 埃索美拉唑镁的晶型
CN102924435B (zh) * 2011-11-25 2014-06-25 成都自豪药业有限公司 S-奥美拉唑镁盐的晶型及其制备方法
WO2013088272A1 (en) * 2011-12-14 2013-06-20 Wockhardt Limited Pharmaceutical composition comprising esomeprazole magnesium dihydrate
MX2014007935A (es) 2011-12-28 2014-11-14 Pozen Inc Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico.
CN102584792B (zh) * 2012-01-06 2014-06-11 南京优科生物医药研究有限公司 制备高纯度的埃索美拉唑盐的方法
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
CN104250243B (zh) * 2013-06-27 2016-12-28 四川国为制药有限公司 一种埃索美拉唑镁二水合物a晶型的制备方法
CN103570686B (zh) * 2013-10-14 2015-04-01 哈药集团技术中心 一种埃索美拉唑钠的合成及精制工艺
CN104725357A (zh) * 2013-12-24 2015-06-24 苏州联友制药技术有限公司 一种埃索美拉唑镁二水合物晶型b的制备方法
FR3018812A1 (fr) * 2014-03-21 2015-09-25 Minakem Nouvelle phase intermediaire de la forme a du sel de magnesium dihydrate d'un enantiomere de l'omeprazole
CN104447699A (zh) * 2014-12-10 2015-03-25 哈药集团技术中心 一种埃索美拉唑镁三水合物的制备方法
CN105111188B (zh) * 2015-08-19 2018-01-19 扬子江药业集团有限公司 一种埃索美拉唑镁三水合物晶型的制备方法
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN106397402B (zh) * 2016-08-30 2019-05-03 山东罗欣药业集团股份有限公司 一种埃索美拉唑镁晶型化合物及其制备方法
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US5244891A (en) * 1985-08-05 1993-09-14 Bristol-Myers Squibb Company Injectable compositions of cefepime dihydrochloride hydrate
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5360582A (en) 1991-07-15 1994-11-01 Minnesota Mining And Manufacturing Company Nonlinear optical materials containing polar disulfone-functionalized molecules
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
FR2719045B1 (fr) * 1994-04-20 1996-05-31 Rhone Poulenc Chimie Procédé de préparation d'acide L-aspartique à partir d'aspartate d'ammonium.
DK0723436T3 (da) 1994-07-08 2001-11-26 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
EP0792879B1 (en) * 1994-11-14 2001-02-28 Daiichi Pharmaceutical Co., Ltd. Process for preparing 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
CN1042423C (zh) 1995-05-25 1999-03-10 常州市第四制药厂 奥美拉唑盐水合物及其制备方法
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion

Also Published As

Publication number Publication date
DE69829511T2 (de) 2006-02-16
CA2521391C (en) 2009-09-29
US8076361B2 (en) 2011-12-13
MEP18008A (en) 2010-10-10
HUP0001849A2 (hu) 2002-05-29
SI1273581T1 (et) 2005-08-31
SK285137B6 (sk) 2006-07-07
WO1998054171A1 (en) 1998-12-03
EG24291A (en) 2009-01-08
NO995852L (no) 2000-01-31
IS2142B (is) 2006-09-15
EP1273581B1 (en) 2005-03-23
KR20050042827A (ko) 2005-05-10
ME00198B (me) 2011-02-10
RS20070459A (en) 2008-06-05
JP2007161734A (ja) 2007-06-28
ES2195345T7 (es) 2014-01-15
US20050075369A1 (en) 2005-04-07
YU60999A (sh) 2002-03-18
HU0001849D0 (et) 2002-05-29
TW538040B (en) 2003-06-21
HU225987B1 (en) 2008-02-28
PT1273581E (pt) 2005-06-30
EP0984957B1 (en) 2003-05-02
US8466175B2 (en) 2013-06-18
KR20010013126A (ko) 2001-02-26
JP4002303B2 (ja) 2007-10-31
US6677455B2 (en) 2004-01-13
NO2012011I1 (no) 2012-06-18
ATE291574T1 (de) 2005-04-15
CY2012029I2 (el) 2015-08-05
RU2184115C2 (ru) 2002-06-27
SA98190280B1 (ar) 2006-07-04
CN1161351C (zh) 2004-08-11
PL193546B1 (pl) 2007-02-28
ES2195345T3 (es) 2003-12-01
HRP980263A2 (en) 1999-02-28
SA05260296B1 (ar) 2008-04-16
PL337180A1 (en) 2000-08-14
SI0984957T1 (en) 2003-10-31
KR100527804B1 (ko) 2005-11-15
SK162599A3 (en) 2000-06-12
SE9702065L (sv) 1998-12-01
US20080255363A1 (en) 2008-10-16
AR059589A2 (es) 2008-04-16
SE510650C2 (sv) 1999-06-14
IS5272A (is) 1999-11-25
ATE239011T1 (de) 2003-05-15
DK1273581T3 (da) 2005-06-06
US20020198239A1 (en) 2002-12-26
UA60334C2 (uk) 2003-10-15
RS50005B (sr) 2008-09-29
EP0984957A1 (en) 2000-03-15
CN1258295A (zh) 2000-06-28
SE9702065D0 (sv) 1997-05-30
WO1998054171A8 (en) 1999-12-23
DE69814069T2 (de) 2004-04-01
US20110130570A1 (en) 2011-06-02
ID29306A (id) 2001-08-16
NZ500991A (en) 2001-05-25
DE122012000017I1 (de) 2012-08-16
MY120745A (en) 2005-11-30
MEP24908A (en) 2010-10-10
DK0984957T3 (da) 2003-06-30
ES2236407T3 (es) 2005-07-16
JP2002501529A (ja) 2002-01-15
LU91871I2 (fr) 2011-11-21
US6369085B1 (en) 2002-04-09
US7745466B2 (en) 2010-06-29
RS50067B (sr) 2009-01-22
HRP980263B1 (en) 2002-02-28
BR9809509A (pt) 2000-06-20
CA2290963C (en) 2006-03-28
AR012717A1 (es) 2000-11-08
DE69829511D1 (de) 2005-04-28
MA26500A1 (fr) 2004-12-20
EP1273581A1 (en) 2003-01-08
DE69814069D1 (de) 2003-06-05
IS2774B (is) 2012-03-15
EE9900550A (et) 2000-06-15
HK1051681A1 (en) 2003-08-15
CA2521391A1 (en) 1998-12-03
DZ2495A1 (fr) 2003-01-25
HUP0001849A3 (en) 2003-02-28
KR100540720B1 (ko) 2006-01-12
CZ297585B6 (cs) 2007-01-10
NO995852D0 (no) 1999-11-29
US7411070B2 (en) 2008-08-12
IS8368A (is) 2006-03-22
NO2011010I1 (no) 2011-06-20
MY127793A (en) 2006-12-29
IL132947A0 (en) 2001-03-19
DE69814069T3 (de) 2014-03-27
AU7793598A (en) 1998-12-30
AU722839B2 (en) 2000-08-10
HK1025962A1 (en) 2000-12-01
CY2012029I1 (el) 2015-08-05
US20120252847A1 (en) 2012-10-04
TNSN98074A1 (fr) 2005-03-15
TR199902934T2 (xx) 2000-04-21
PT984957E (pt) 2003-07-31
SK284837B6 (sk) 2005-12-01
ZA984179B (en) 1998-11-30
NO317518B1 (no) 2004-11-08
CA2290963A1 (en) 1998-12-03
EP0984957B3 (en) 2013-09-18
LU92017I2 (fr) 2012-08-06

Similar Documents

Publication Publication Date Title
EE03875B1 (et) S-omeprasooli uus vorm
EE9900259A (et) Ühendi uus vorm
IS6239A (is) Ný efnasambönd
NO20002571L (no) Emballasje
ATE260583T1 (de) Spender
NO20000677D0 (no) Brønnhode
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
DK1261585T3 (da) Substituerede indol-Mannichbaser
IS6139A (is) Ný efnasambönd
PT1237857E (pt) Novos derivados fenalquiloxi-fenilo
NO20015510D0 (no) Medikament for lokal påföring
EE200000022A (et) Uus ravimvorm
EE9900391A (et) Uus protsess
DE60037421D1 (de) Stopfbuchspackung
IS6141A (is) Ný efnasambönd
DK1317256T3 (da) Farmaceutisk sammensætning havende en modificeret bærer
IT249842Y1 (it) Fissaggio a incastro per un cassetto sospeso
DE50106325D1 (de) Liganden von integrinrezeptoren
EE200100381A (et) Morfolinobensamiidi uued soolad
EE200100084A (et) NOS inhibiitorite uued farmatseutilised kasutusvoimalused
EE9900455A (et) Uus menetlus
NO20020257D0 (no) Nedihullspakning-oppumpingsstyreanordning
DE50008657D1 (de) Verpackungsklebebänder
DE29901077U1 (de) Kleiderbügel
DE50012960D1 (de) Verpackungsklebebänder

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name
AA1Y Spc filed

Free format text: PRODUCT NAME: VIMOVO; REG NO/DATE: 714110 23.11.2010

Spc suppl protection certif: C20110007

Filing date: 20110516

FG1Y Spc granted

Free format text: PRODUCT NAME: VIMOVO;REG NO/DATE: 714110 23.11.2010

Spc suppl protection certif: C20110007 00061

Filing date: 20110516

Extension date: 20230525

Free format text: PRODUCT NAME: VIMOVO;REG NO/DATE: 714110 23.11.2010

Spc suppl protection certif: C20110007 00061

Filing date: 20110516

Extension date: 20310516